Biota Pharmaceuticals to Participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference

Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's executive team will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference being held at the Langham Hotel on Tuesday, December 15, 2015 in Boston, MA.

About Biota Pharmaceuticals, Inc.

Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company's ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase 1 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.

Biota is a registered trademark of Biota Pharmaceuticals, Inc.

CONTACT: Mark Colonnese
         Executive Vice President and Chief Financial Officer
         [phone]
         [e-mail]
         
         Sarah McCabe
         Stern Investor Relations, Inc.
         [phone]
         [e-mail]